Immunogenicity and Safety of a Novel 13-Valent Pneumococcal Vaccine in Healthy Chinese Infants and Toddlers
Authors:
Open Access
- 9 May 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 13, 870973
Abstract
Background: To determine the non-inferiority of the seven common serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) in the 13-valent pneumococcal conjugate vaccine (PCV13) with each serotype conjugated to a tetanus toxoid carrier protein and adsorbed on aluminum phosphate and the superiority of its six additional serotypes (1, 3, 5, 6A, 7F, and 19A) to the serotypes in the PCV7.Methods: Participants were evenly randomized in a 1:1 ratio into either the PCV13 or PCV7 groups, to receive three doses of the vaccine at the age of 3, 4, and 5 months, respectively, and a booster dose between 12 and 15 months of age. Serotype-specific antibodies were measured using a standardized enzyme-linked immunosorbent assay (ELISA) and opsonophagocytic activity (OPA) microcolony assay method.Results: A total of 1,040 healthy infants were enrolled. All the seven common serotypes in the PCV13 were non-inferior to those in the PCV7 in terms of the serotype-specific IgG production induced; however, non-inferiority was not shown for serotype 6B after the infant series. The proportion of subjects who reached OPA antibody titers ≥ 1:8 in the PCV13 group was 89.25% or higher. Local reactions and systemic events were mild or moderate in severity and similar between the two groups. No new safety signals were observed.Conclusion: The newly developed PCV13 was immunogenic for all serotypes and had a comparable safety profile to the marketed PCV7.Keywords
This publication has 27 references indexed in Scilit:
- Multiple Testing Problems in Pharmaceutical Statistics. A.Dmitrienko, A. C.Tamhane, and F.Bretz (2010). Boca Raton:Chapman & Hall/CRC Biostatistics Series. ISBN: 978‐1‐584 88984‐7Biometrical Journal, 2012
- Burden of Pneumonia and Meningitis Caused by Streptococcus pneumoniae in China among Children under 5 Years of Age: A Systematic Literature ReviewPLOS ONE, 2011
- Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Infants and ToddlersPediatrics, 2010
- Recommendations for the Prevention of Streptococcus pneumoniae Infections in Infants and Children: Use of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Pneumococcal Polysaccharide Vaccine (PPSV23)Pediatrics, 2010
- Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared to Those of a 7-Valent Pneumococcal Conjugate Vaccine Given as a Three-Dose Series with Routine Vaccines in Healthy Infants and ToddlersClinical and Vaccine Immunology, 2010
- Challenges in the evaluation and licensing of new pneumococcal vaccines, 7–8 July 2008, Ottawa, CanadaVaccine, 2009
- Safety and immunogenicity of a 7-valent pneumococcal conjugate vaccine (Prevenar™): Primary dosing series in healthy Chinese infantsVaccine, 2008
- Micro-colony array based high throughput platform for enzyme library screeningJournal of Biotechnology, 2007
- Enzyme-Linked Immunosorbent Assay for Quantitation of Human Antibodies to Pneumococcal PolysaccharidesClinical and Vaccine Immunology, 2003
- THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIALBiometrika, 1934